Screener
Mesa Laboratories MLAB Clinical Genomics — Inventory Net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026808
FAQ
- What is Mesa Laboratories's clinical genomics — inventory net?
- Mesa Laboratories (MLAB) reported clinical genomics — inventory net of $9.26M in Q2 2026.
- How has Mesa Laboratories's clinical genomics — inventory net changed year-over-year?
- Mesa Laboratories's clinical genomics — inventory net decreased by 7.5% year-over-year, from $10.01M to $9.26M.
- What is the long-term trend for Mesa Laboratories's clinical genomics — inventory net?
- Over 2 years (2023 to 2026), Mesa Laboratories's clinical genomics — inventory net has grown at a -18.1% compound annual growth rate (CAGR), from $53.89M to $36.18M.
- What does clinical genomics — inventory net mean?
- Represents the net value of inventory held by the Clinical Genomics segment after accounting for reserves, obsolescence, and write-downs. This metric reflects the capital tied up in raw materials, work-in-progress, and finished goods specifically for genetic analysis tools. Monitoring this helps assess inventory turnover efficiency and potential risks of product obsolescence in a high-tech manufacturing environment.
Ask your AI about Mesa Laboratories's clinical genomics — inventory net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude